Clinical trials eligibility of patients with malignant pleural mesothelioma: use of novel therapies and outcomes

B Lau, M Boyer, JH Lee, S Kao - Clinical Lung Cancer, 2020 - Elsevier
Introduction Studies of bevacizumab and pembrolizumab in the treatment of malignant
pleural mesothelioma suggest anticancer efficacy; clinical trial populations are not reflective …
被引用次数：8 相关文章

Clinical trials eligibility of patients with malignant pleural mesothelioma: use of novel therapies and outcomes

B Lau, M Boyer, JH Lee, S Kao - Clinical Lung Cancer, 2020 - researchers.mq.edu.au
Introduction: Studies of bevacizumab and pembrolizumab in the treatment of malignant
pleural mesothelioma suggest anticancer efficacy; clinical trial populations are not reflective …

Clinical Trials Eligibility of Patients With Malignant Pleural Mesothelioma: Use of Novel Therapies and Outcomes

B Lau, M Boyer, JH Lee, S Kao - Clinical Lung Cancer, 2020 - clinical-lung-cancer.com
Introduction Studies of bevacizumab and pembrolizumab in the treatment of malignant
pleural mesothelioma suggest anticancer efficacy; clinical trial populations are not reflective …

Clinical Trials Eligibility of Patients With Malignant Pleural Mesothelioma: Use of Novel Therapies and Outcomes

B Lau, M Boyer, JH Lee, S Kao - Clinical lung cancer, 2020 - pubmed.ncbi.nlm.nih.gov
Introduction Studies of bevacizumab and pembrolizumab in the treatment of malignant
pleural mesothelioma suggest anticancer efficacy; clinical trial populations are not reflective …

Clinical Trials Eligibility of Patients With Malignant Pleural Mesothelioma: Use of Novel Therapies and Outcomes.

B Lau, M Boyer, JH Lee, S Kao - Clinical Lung Cancer, 2020 - europepmc.org
Results A total of 133 patients were included: 50% and 37%, respectively, did not meet trial
eligibility for MAPS or KEYNOTE-028, most commonly owing to age≥ 75 (23%), Eastern …